Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ore Pharmaceuticals Inc.
Ore Pharmaceuticals CEO Charles Dimmler Presents Compound Status and Patent Development at Rodman & Renshaw 5th Annual Global Healthcare Conference
June 3rd, 2008
Ore Pharmaceuticals Inc. (NASDAQ: ORXE) announced that Chief Executive Officer and President Charles L. Dimmler, III, gave a presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference, that included certain research and development findings, the Company's current compound development status, and information about its recently published patent application regarding stratification and treatment of the majority of breast cancer patients based on their estrogen receptor alpha status. Research and Development Findings Mr. Dimmler presented the Company's findings resulting from its integrative pharmacology capability. Ore Pharmaceuticals...
Source: Cancer Weekly (2008-06-03)
|
